As Biogen gets squishy on timing for aducanumab filing, the clock is ticking

As Biogen gets squishy on timing for aducanumab filing, the clock is ticking

STAT Plus: As Biogen gets squishy on timing for an aducanumab filing, the clock is ticking

By ADAM FEUERSTEIN

RUBY WALLAU FOR STAT

Baird analyst Brian Skorney says Biogen deserves criticism for its evasiveness on the issue of when it will submit its Alzheimer's drug to the FDA.

READ MORE